Wall Street Journal
The drug metformin, a mainstay of diabetes care for 15 years, may have a new life as a cancer treatment, researchers said.
In a study in mice, low doses of the drug, combined with a widely used chemotherapy called doxorubicin, shrank breast-cancer tumors and prevented their recurrence more effectively than chemotherapy alone.
The findings add to a growing body of evidence that metformin, marketed as Glugophase by Bristol-Myers Squibb Co. and available in generic versions, could be a potent antitumor medicine... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
